Ronald A. Rader

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.

FDA inspections can create uncertainty. Supervision of the contract manufacturer is crucial in ensuring compliance.

Outsourcing of manufacturing activities is expected to increase in 2019.

The growth in adoption of single-use systems for commercial manufacturing will be dramatic in coming years.